Sign in

Mike Weedon

@mnweedon.bsky.social
195 followers 260 following 4 posts
PostsRepliesMedia
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 09/02/2026
Some exciting openings in Exeter for clinical academics (professor and senior lecturer). Come and shape the future of translational genomic medical research in the South West! Lovely place to work, lovely people to work with, and freedom to pursue great science... www.linkedin.com/jobs/view/43...
075
Reposted by Mike Weedon
Harry Wright @hiwwright.bsky.social · 06/02/2026
Excited to share my first preprint on federated conditional analysis of rare single variant and aggregate association tests across six genetically-inferred ancestry groups in All of Us and UK Biobank doi.org/10.64898/202...
12211
Reposted by Mike Weedon
bioRxiv Genetics @biorxiv-genetic.bsky.social · 05/02/2026
Federated cross-biobank conditional analysis identifies LDL-C lowering effects of DNAJC13 haploinsufficiency and LDLR regulation www.biorxiv.org/content/10.64898/20…
011
Reposted by Mike Weedon
Ian Sudbery @iansudbery.bsky.social · 27/01/2026
I'm now hearing that the pause at BBSRC might last a while year. This is absolutely devastating for British biology. The number of young postdocs while will be lost to science is innumerable.
002
Reposted by Mike Weedon
Ian Sudbery @iansudbery.bsky.social · 23/01/2026
I've now heard (fourth hand) that members of boards have been told that they should only consider 15 applications at the next board, and that they should only recommend 3 for award. These boards receive over 100 applications, and would usually be expected to award around 15! So that's 1/5 of normal!
201
Reposted by Mike Weedon
Ian Sudbery @iansudbery.bsky.social · 23/01/2026
I'm seeing relatively little chatter or outcry about what is happening at the MRC, the UK's biomedical research funder. Before Christmas MRC paused the acceptance of many of its grants, including the standard applicant-led research grant. There has been no public information on what is happening 🧵
41421
Reposted by Mike Weedon
Kartik Chundru @chundru.bsky.social · 17/11/2025
Please forward this to any you know who could be interested! The incredible @drghawkes.bsky.social will be leading a course on analysis of genome sequence data, functional annotation of the genome, and using the very, very exciting AlphaGenome tool
021
Mike Weedon @mnweedon.bsky.social · 17/11/2025
If you are looking to learn about rare variant WGS analyses, AlphaGenome and lots more, come join us in Exeter next September. It’s going to be a great few days!
000
Reposted by Mike Weedon
Dr Gareth Hawkes @drghawkes.bsky.social · 10/11/2025
Genomic superstar @chundru.bsky.social taking on fake-news genotypes in >900k individuals. He shows allele-level filtering is rarely suffifient, and makes the brave choice to properly tackle chrX! We’ll be providing our filtered AoU WGS plink pgens for all registered users: watch this space
074
Reposted by Mike Weedon
Kartik Chundru @chundru.bsky.social · 08/11/2025
New paper on everyone’s favourite topic, QC! We show why you should do genotype-level QC on your WGS data www.biorxiv.org/content/10.1... Very real quotes about this paper - “The most exciting, mind-blowing paper of the year!” “On a par with Fisher 1918” “I read it every night. Just so beautiful”
biorxiv.org
Genotype-level quality control substantially reduces error rates in population-scale whole-genome sequencing
Population-scale whole-genome sequencing data will contain many individual-level genotype errors, even after allele-level quality control (QC). We establish the need for genotype-level QC using UK Bio...
24619
Reposted by Mike Weedon
Kartik Chundru @chundru.bsky.social · 08/11/2025
Thank you to other co-authors @carolinefwright.bsky.social, @mnweedon.bsky.social, @timfrayling.bsky.social, and @drarwood.bsky.social, @nihrexeterbrc.bsky.social, biobanks @ukbiobank.bsky.social and All of Us, and all of the participants of the studies
141
Reposted by Mike Weedon
Luke Sharp @luke-sharp.bsky.social · 03/11/2025
Excited to announce the acceptance and publication of our paper titled “Population prevalence, penetrants, and mortality for genetically confirmed MODY” in JCEM: doi.org/10.1210/clin... #MODY #monogenicdiabetes
doi.org
Population prevalence, penetrance, and mortality for genetically confirmed MODY
AbstractContext. Diagnosing Maturity-Onset Diabetes of the Young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studi
094
Mike Weedon @mnweedon.bsky.social · 03/11/2025
Population prevalence, penetrance, and mortality for genetically confirmed MODY: academic.oup.com/jcem/article...
academic.oup.com
Population prevalence, penetrance, and mortality for genetically confirmed MODY
AbstractContext. Diagnosing Maturity-Onset Diabetes of the Young (MODY) is clinically important for treatment and prognosis. However, phenotype-based studi
030
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 29/10/2025
Excellent autumnal away-day by the seaside with the Exeter genomics teams, organised by @drghawkes.bsky.social, discussing improvements to our whole genome sequence annotation and burden-testing pipelines - lots more exciting science to come! @exeter.ac.uk @nihrexeterbrc.bsky.social
052
Reposted by Mike Weedon
Andrea Ganna @andganna.bsky.social · 16/10/2025
🎉 New preprint out! "Removing genetic effects on plasma proteins enhances their utility as disease biomarkers" We show that adjusting plasma proteins for genetic effects can make them stronger predictors of disease 👉 doi.org/10.1101/2025...
12911
Reposted by Mike Weedon
Nature Metabolism @natmetabolism.nature.com · 14/10/2025
RESEARCH | J Murray Leech, KA Patel et al. @exeter.ac.uk Polygenic risk for T2D modifies the onset and phenotypic variability of maturity-onset diabetes of the young (MODY) 🧪
bit.ly
Common genetic variants modify disease risk and clinical presentation in monogenic diabetes - Nature Metabolism
In clinical and population-based cohorts, a strong contribution of polygenic risk for type 2 diabetes (T2D) significantly modifies the onset and phenotypic variability of maturity-onset diabetes of the young (MODY). This polygenic T2D burden may also account for MODY-like individuals without identified monogenic causes.
083
Reposted by Mike Weedon
James Russ-Silsby @jamesr-s.bsky.social · 15/09/2025
I’m excited to share the 2 newest Neonatal diabetes genes: RNU4ATAC and RNU6ATAC. These genes encode snRNA components of the minor spliceosome and biallelic variants in them cause monogenic autoimmune diabetes. If you are at #EASD, come to Matt Johnson’s talk Tuesday @4pm in Milan hall to hear more.
medrxiv.org
The minor spliceosome is a master immune regulator
Pathogenic variants in non-coding genes are emerging as critical contributors to human rare diseases. We identified 19 individuals with early-onset diabetes (diagnosed <5 years) and additional clinica...
067
Reposted by Mike Weedon
Nature Metabolism @natmetabolism.nature.com · 09/09/2025
bit.ly
Common genetic variants modify disease risk and clinical presentation in monogenic diabetes
Nature Metabolism, Published online: 09 September 2025; doi:10.1038/s42255-025-01372-0In clinical and population-based cohorts, a strong contribution of polygenic risk for type 2 diabetes (T2D) significantly modifies the onset and phenotypic variability of maturity-onset diabetes of the young (MODY). This polygenic T2D burden may also account for MODY-like individuals without identified monogenic causes.
032
Reposted by Mike Weedon
Jacques Murray Leech @jacquesml.bsky.social · 09/09/2025
Now out in @natmetabolism.nature.com! Excited to share our work showing how common genetic changes shape how diabetes presents in MODY (Maturity-Onset Diabetes of the Young). Our findings highlight the growing overlap between monogenic and polygenic forms of diabetes. www.nature.com/articles/s42...
nature.com
Common genetic variants modify disease risk and clinical presentation in monogenic diabetes - Nature Metabolism
In clinical and population-based cohorts, a strong contribution of polygenic risk for type 2 diabetes (T2D) significantly modifies the onset and phenotypic variability of maturity-onset diabetes of th...
163
Reposted by Mike Weedon
Aparajita Sriram @aparajita-sriram.bsky.social · 27/08/2025
Our paper is now out on Diabetes! diabetesjournals.org/diabetes/art...
diabetesjournals.org
Rare Variants in NEUROD1 and PDX1 Are Low-Penetrance Causes of MODY, Whereas Those in APPL1 and WFS1 Are Not Associated With MODY
An accurate genetic diagnosis of maturity-onset diabetes of the young (MODY) is critical for personalized treatment. To avoid misdiagnosis, only genes with
034
Reposted by Mike Weedon
Jacques Murray Leech @jacquesml.bsky.social · 11/08/2025
New preprint out now! We show polygenic background shapes GCK-MODY clinical presentation. In >1,000 cases, higher polygenic risk increased the chance of exceeding diagnostic diabetes thresholds, highlighting how monogenic & polygenic factors jointly shape disease. #Genetics
196
Reposted by Mike Weedon
Robin Hofmeister @rjhfmstr.bsky.social · 06/08/2025
🚨 Our parent-of-origin study is out in Nature! 🧬 Maternal and paternal alleles can have distinct — even opposite — effects on human traits, revealing a hidden layer of genetic architecture that standard GWAS miss. 🔗 www.nature.com/articles/s41... Highlights below!
211755
Reposted by Mike Weedon
erinltempleman.bsky.social @erinltempleman.bsky.social · 23/07/2025
🚨Big news! Excited to share my first PhD paper!🎉 We validated & improved a T1D risk model using TrialNet data (originally from TEDDY), boosting accuracy 📈 bmcmedicine.biomedcentral.com/articles/10.... Try the web tool 👉 t1dpredictor.diabetesgenes.org #T1D #RiskPrediction #PrecisionMedicine #TrialNet
bmcmedicine.biomedcentral.com
Development and recalibration of a multivariable type 1 diabetes prediction model for type 1 diabetes across multiple screening studies - BMC Medicine
Background Accurate type 1 diabetes prediction is important to facilitate screening for pre-clinical type 1 diabetes to enable potential early disease-modifying interventions and to reduce the risk of...
0115
Reposted by Mike Weedon
The Lancet Diabetes & Endocrinology @thelancetendo.bsky.social · 22/07/2025
New Research: Non-autoimmune, insulin-deficient #diabetes in children and young adults in #Africa: evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) cross-sectional study thelancet.com/journals/lan... #T1D #OpenAccess #MedSky #EndoSky
thelancet.com
Non-autoimmune, insulin-deficient diabetes in children and young adults in Africa: evidence from the Young-Onset Diabetes in sub-Saharan Africa (YODA) cross-sectional study
In sub-Saharan Africa, clinically diagnosed type 1 diabetes is heterogeneous, comprising classic autoimmune type 1 diabetes and a novel, non-autoimmune, insulin-deficient diabetes subtype. There is ev...
154
Reposted by Mike Weedon
James Russ-Silsby @jamesr-s.bsky.social · 03/07/2025
Really proud of this Exeter–Stanford collaboration identifying bi-allelic variants in PAX4 as a novel cause of transient neonatal diabetes—the first new genetic cause of this subtype described in over a decade. This work expands our understanding of beta cell development. 🔗 doi.org/10.1016/j.mo...
sciencedirect.com
Complete Loss of PAX4 causes Transient Neonatal Diabetes in Humans
Gene discovery studies in individuals with diabetes diagnosed within 6 months of life (neonatal diabetes, NDM) can provide unique insights into the de…
1148
Reposted by Mike Weedon
medRxivpreprint @medrxivpreprint.bsky.social · 01/07/2025
Population prevalence, penetrance, and mortality for genetically confirmed MODY www.medrxiv.org/content/10.1101/202…
034
Reposted by Mike Weedon
Zoltán Kutalik @zkutalik.bsky.social · 27/06/2025
Lausanne Comp Bio Symposium 2025 (cbiosymposium.unil.ch) 🗓 Abstract deadline 30 June (𝟑 𝐝𝐚𝐲𝐬 𝐭𝐨 𝐠𝐨!!!) 🎤 Oral presentation notifications: 7 July ✅ Early Bird registration deadline: 11 July 💰 Registration fee for non-PI: 150 CHF
088
Reposted by Mike Weedon
Luke Sharp @luke-sharp.bsky.social · 19/06/2025
MODY is prevalent in later onset diabetes. Really proud to announce the release of a preprint of our paper assessing MODY in people diagnosed with diabetes later in life!! #MonogenicDiabetes
066
Reposted by Mike Weedon
Anna Gloyn @annagloyn.bsky.social · 05/06/2025
Out today from #HectorOrtega & #SethASharp A state of the art review on polygenic risk scores (#PRS) in diabetes. This is your #101 on what we currently know about them and their application to understanding disease heterogeneity & clinical translation. Read for free here - rdcu.be/eprel
096
Reposted by Mike Weedon
Aparajita Sriram @aparajita-sriram.bsky.social · 04/06/2025
Excited to share the preprint of our paper (my first paper!) looking at limited evidence MODY genes. We use rare variant burden testing and one of the largest MODY cohorts to evaluate the pathogenicity of these genes. This evidence can help inform clinical guidelines in MODY genetic testing!
034
Reposted by Mike Weedon
James Fasham @jamesfasham.bsky.social · 22/05/2025
Congratulations @carolinefwright.bsky.social for being elected to a fellow of the Academy of Medical Sciences! 🍾! news.exeter.ac.uk/faculty-of-h... @nihrexeterbrc.bsky.social
news.exeter.ac.uk
Genomic medicine scientist elected to prestigious fellowship
An expert in genomic medicine at Exeter has been recognised for her outstanding contribution to the field of medical sciences. Professor Caroline Wright is one of the 54 exceptional biomedical and hea...
1103
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 01/05/2025
⬇️ again. I feel the need to re-post this point pretty much every week! Benign variants are not low penetrance.
041
Reposted by Mike Weedon
Amber Luckett @ambermluckett.bsky.social · 25/04/2025
Our new paper updating GRS2 with a new tool to easily generate standardised T1DGRS 🧬 Thanks to Seth Sharp, @annagloyn.bsky.social, Richard Oram and @mnweedon.bsky.social for a great collaboration! tinyurl.com/4bsaz9hx
tinyurl.com
Standardized Measurement of Type 1 Diabetes Polygenic Risk Across Multiancestry Population Cohorts
Amber M. Luckett, Richard A. Oram, Aaron J. Deutsch, Hector I. Ortega, Diane P. Fraser, Kaavya Ashok, Alisa K. Manning, Josep M. Mercader, Manuel A. Rivas,
022
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 10/04/2025
"Remember that it's not only scientists that read your papers" - sage advice from author of a beautiful poem 'Proband', which began life as a response to our DDD NEJM paper, linking genomic science and its patients. www.consilience-journal.com/issue-17-pro...
consilience-journal.com
Proband — Consilience
2136
Reposted by Mike Weedon
James Russ-Silsby @jamesr-s.bsky.social · 04/04/2025
There are fewer than 10 documented genetic causes of Transient Neonatal Diabetes (TNDM) and now PAX4 is one of them! Really proud of this collaborative work done between the Neonatal Diabetes Research Team at Exeter and the Translational Genomics of Diabetes Lab in Stanford.
0118
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 03/04/2025
Come and work with us - 2 Graduate Research Assistant positions available in genomic medicine, with a particular focus on variant interpretation and data analysis. Part of the Wellcome-funded PARADIGM project, and based in beautiful Exeter UK! jobs.exeter.ac.uk/hrpr_webrecr...
095
Reposted by Mike Weedon
Jeff Spence @jeffspence.github.io · 28/03/2025
A really nice paper by @drghawkes.bsky.social et al. argues that rare and common genetic associations converge on the same genes. While this seems at odds with our recent work about how burden tests and GWAS prioritize different genes, our results agree (🧬🧪🧵 1/6) www.biorxiv.org/content/10.1...
biorxiv.org
Whole-genome sequencing analysis of anthropometric traits in 672,976 individuals reveals convergence between rare and common genetic associations
Genetic association studies have mostly focussed on common variants from genotyping arrays or rare protein-coding variants from exome sequencing. Here, we used whole-genome sequence (WGS) data in 672,...
65922
Reposted by Mike Weedon
Dr Gareth Hawkes @drghawkes.bsky.social · 24/03/2025
Excited to be able to announce I’ll be starting a 5-year MRC Career Development Award fellowship next week on the 1st April at the University of Exeter! Lots of work to do on whole genomes, and I’m hoping to keep contributing my small piece!
3161
Reposted by Mike Weedon
Daniel MacArthur @dgmacarthur.bsky.social · 15/03/2025
New preprint! We worked with @msftresearch.bsky.social and @broadinstitute.org to see whether large language models (LLMs) can be useful to variant scientists in deciding whether genetic variants seen in a patient are responsible for their disease. tl;dr yes they can: www.biorxiv.org/content/10.1...
biorxiv.org
Evidence Aggregator: AI reasoning applied to rare disease diagnostics
Retrieving, reviewing, and synthesizing technical information can be time-consuming and challenging, particularly when requiring specialized expertise, as is the case of variant assessment for rare di...
114247
Reposted by Mike Weedon
Caroline Wright @carolinefwright.bsky.social · 27/02/2025
Exciting times for genomics research @exeter.ac.uk @nihrexeterbrc.bsky.social! 🧬 New preprint from the team: using large-scale WGS from @ukbiobank.bsky.social and All of Us shows convergence between rare and common genetic associations, with implications for genetic architecture of complex traits.
054
Reposted by Mike Weedon
Dr Gareth Hawkes @drghawkes.bsky.social · 26/02/2025
This was a really fun and exciting project to work on, and hopefully shows we're not near to exhausting population-scale WGS data. A great collaboration led by @mnweedon.bsky.social @drarwood.bsky.social and @carolinefwright.bsky.social , with @chundru.bsky.social and @rnbeaumont.bsky.social
111
Reposted by Mike Weedon
John Dennis @johndennis.bsky.social · 26/02/2025
5-drug precision prescribing for people with type 2 diabetes is here Our model for optimising glucose lowering therapy using low-cost routine clinical features published in the Lancet today Paper: thelancet.com/journals/lan... Try the web tool here: diabetesgenes.org/t2-treatment/
thelancet.com
A five-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study
We have developed a five-drug class model that uses routine clinical data to identify optimal glucose-lowering therapies for people with type 2 diabetes. Individuals on model-predicted optimal therapy...
298
Reposted by Mike Weedon
University of Exeter @exeter.ac.uk · 26/02/2025
Millions of people with type 2 diabetes could receive better treatment thanks to a new, simple low-cost tool, according to groundbreaking research announced today at the Diabetes UK Professional Conference and published in the Lancet. 1/3
185
Reposted by Mike Weedon
Mike Inouye @mikeinouye.bsky.social · 25/02/2025
Exeter doing some great stuff with biobank scale WGS at the moment! Whole-genome sequencing analysis of anthropometric traits in 672,976 individuals reveals convergence between rare and common genetic associations www.biorxiv.org/content/10.1...
biorxiv.org
Whole-genome sequencing analysis of anthropometric traits in 672,976 individuals reveals convergence between rare and common genetic associations
Genetic association studies have mostly focussed on common variants from genotyping arrays or rare protein-coding variants from exome sequencing. Here, we used whole-genome sequence (WGS) data in 672,...
0306
Mike Weedon @mnweedon.bsky.social · 26/02/2025
Whole-genome sequencing analysis of anthropometric traits in 672,976 individuals reveals convergence between rare and common genetic associations: tinyurl.com/ye2yhx9t
tinyurl.com
000
Reposted by Mike Weedon
Dr Gareth Hawkes @drghawkes.bsky.social · 24/02/2025
Excited to finally share that our paper looking at the effect of rare non-coding variants using WGS on circulating protein levels in the UKB has been released in Nature Genetics @naturegenet.bsky.social! We now analyse the full 3,000 circulating proteins in all 50,000 individuals rdcu.be/ea16i
rdcu.be
Whole-genome sequencing analysis identifies rare, large-effect noncoding variants and regulatory regions associated with circulating protein levels
Nature Genetics - Rare variant association analysis of plasma proteins using whole-genome sequencing data in 54,306 individuals in the UK Biobank demonstrates that combining both single-variant and...
13219
Reposted by Mike Weedon
Dr Gareth Hawkes @drghawkes.bsky.social · 18/02/2025
We’re hiring! Looking for a motivated data scientist/bio-informatician to join our team analysing WGS across biobanks via meta analysis, with a focus on T2D and its related traits. Please get in touch if you’re interested! tinyurl.com/3wdfc2me
tinyurl.com
Powered by MHR
002
Mike Weedon @mnweedon.bsky.social · 07/02/2025
A great opportunity to join us in Exeter as a Lecturer in Health Data Science: tinyurl.com/2sy7w2y5. Please get in touch if you're interested!
tinyurl.com
Powered by MHR
055
Reposted by Mike Weedon
Andrew Wood @drarwood.bsky.social · 29/01/2025
Excited to see our paper on medRxiv "Streamlining Large-Scale Genomic Data Management: Insights from the UK Biobank Whole-Genome Sequencing Data". Paper here: www.medrxiv.org/content/10.1.... Tools here: github.com/drarwood/vcf....
medrxiv.org
Streamlining Large-Scale Genomic Data Management: Insights from the UK Biobank Whole-Genome Sequencing Data
Biobank-scale Whole-Genome Sequencing (WGS) studies are increasingly pivotal in unraveling the genetic bases of diverse health outcomes. However, managing and analyzing these datasets' sheer volume an...
121